Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications

被引:0
作者
Moritz Reese
Sameer A. Dhayat
机构
[1] University Hospital Muenster,Department of General, Visceral and Transplant Surgery
来源
Journal of Hematology & Oncology | / 14卷
关键词
Pancreatic cancer; Pancreatic ductal adenocarcinoma; Exosome; Small extracellular vesicle; Non-coding RNA; MicroRNA; Long non-coding RNA; Circular RNA;
D O I
暂无
中图分类号
学科分类号
摘要
Pancreatic cancer has the worst prognosis among common tumors which is attributed to its aggressive phenotype, diagnosis at advanced, inoperable stages, and resistance to systemic therapy. Non-coding RNAs (ncRNAs) such as microRNAs, long non-coding RNAs, and circular RNAs have been established as important regulators of gene expression and their deregulation has been implicated in multiple diseases and foremost cancer. In the tumor microenvironment, non-coding RNAs can be distributed among cancer cells, stromal cells, and immune cells via small extracellular vesicles (sEVs), thereby facilitating intercellular communication and influencing major cancer hallmarks such as angiogenesis, evasion of the immune system, and metastatic dissemination. Furthermore, sEV-ncRNAs have shown promising potential as liquid biopsies with diagnostic and prognostic significance. In this review, we summarize the role of sEVs as carriers of ncRNAs and underlying molecular mechanisms in pancreatic cancer. Moreover, we review the potential of sEV-ncRNAs as biomarkers and highlight the suitability of sEVs as delivery vehicles for ncRNA-based cancer therapy.
引用
收藏
相关论文
共 1659 条
[121]  
Mortier E(2011)Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype Clin Cancer Res 17 5822-2381
[122]  
Melchior A(2014)Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma Cancer Res 74 1032-2684
[123]  
Degeest G(2017)Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK Br J Cancer 116 609-2111
[124]  
Geeraerts A(2017)MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma Sci Rep 7 42339-72
[125]  
Ivarsson Y(2006)Cellular pharmacology of gemcitabine Ann Oncol 17 v7-227
[126]  
Depoortere F(2007)Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development Proc Natl Acad Sci USA 104 16170-738
[127]  
Coomans C(2001)Stem cells, cancer, and cancer stem cells Nature 414 105-889
[128]  
Vermeiren E(2020)Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210 Cell Oncol (Dordr) 43 123-3258
[129]  
Mittelbrunn M(2021)Targeting hypoxic tumor microenvironment in pancreatic cancer J Hematol Oncol 14 14-1061.e1018
[130]  
Vicente Manzanares M(2016)Neutral sphingomyelinase (SMPD3) deficiency disrupts the Golgi secretory pathway and causes growth inhibition Cell Death Dis 7 e2488-3610